Browsing Tag
Caplyta
6 posts
J&J’s CAPLYTA nearly doubles remission rates in Phase 3 MDD trial
Find out how Johnson & Johnson’s CAPLYTA is redefining remission in depression with six-month data that could reshape MDD treatment benchmarks.
NYSE: JNJ Q4 earnings rise 49% to $2.10 EPS; oncology and neuroscience lead portfolio momentum
Johnson & Johnson posts $94.2B in 2025 revenue and sets $100.5B FY26 target. Find out what’s driving growth and how STELARA’s erosion could impact momentum.
FDA gives CAPLYTA the go-ahead for major depressive disorder, boosting hopes for better remission rates
Find out how CAPLYTA’s FDA approval for major depressive disorder could redefine depression treatment and improve remission outcomes.
FDA approves JNJ’s CAPLYTA for depression: Is this a new hope for MDD remission?
Johnson & Johnson secures FDA approval for CAPLYTA in major depressive disorder. Find out how this expands safe treatment options for difficult-to-treat depression.
Johnson & Johnson to acquire Intra-Cellular Therapies in $14.6bn deal
Johnson & Johnson has announced its largest biotech acquisition in over a year, agreeing to purchase Intra-Cellular Therapies…
Breakthrough in mental health treatment: Intra-Cellular’s Caplyta emerges as a beacon of hope for schizophrenia patients
In a significant development for schizophrenia management, Intra-Cellular Therapies has announced impressive outcomes from a late-stage, Phase III…